cannabis research

More than 22.2 million Americans engage in past month cannabis use. Over the last several decades, although cannabis users in the US have historically sought out cannabis for recreational purposes, a growing number are exploring cannabis for medicinal reasons. In fact, there are over 1 million registered medical cannabis (MC) consumers in the US, and this number continues to grow as the public becomes increasingly aware of and open to the potential therapeutic effects of cannabis. Legal cannabis is considered the fastest growing market in the United States. As of 2019, 33 states and the District of Columbia have voted to legalize MC, with an additional 15 states providing limited MC access. Further, 11 states and the District of Columbia have also approved adult/recreational cannabis use. Despite these rapid changes in the law, many policy makers, consumers, physicians, and the general public remain misinformed about cannabis.


While there is a growing body of evidence demonstrating alterations in brain structure and function secondary to recreational cannabis use, particularly during vulnerable developmental periods such as adolescence, critical questions regarding the effects of MC remain unanswered. For example, how do recreational and MC use differ? Recreational cannabis and MC, although derived from the same plant species, are often not entirely the same; strains tend to vary in constituent composition, including THC, the main psychoactive component in cannabis, and cannabidiol (CBD), a primary non-intoxicating component. What is the impact of MC on adults with regard to both short and longer term use? MIND is designed to begin to address some of these questions as thus far, little data is available regarding the impact of MC on measures of cognition, sleep, clinical state, quality of life, and brain-related measures. 


Marijuana Investigations for Neuroscientific Discovery (MIND)

  • MIND is the first program of its kind!

  • MIND supports a number of projects designed to examine cannabinoid-based therapies for a range of indications and conditions using longitudinal, observation, cross-sectional, survey, and clinical trial models

  • MIND is dedicated to understanding the impact of medical cannabis (MC) on cognition, clinical state, quality of life, brain structure and function, and related measures

  • For more information about current research projects, click here

  • For publications from the MIND program, click here


MIND is currently funded and supported by:

  • NIDA (1R01 DA048821 01)

  • Philanthropy/private donations

  • Industry


McLean Hospital

115 Mill St

Belmont, MA 02448


To volunteer for research​

Call: 617-855-3653



Call: 617-855-3653

© 2018. Proudly created with